GHRP-6 vs PT-141: What Is the Difference?
Two short synthetic molecules, both with accidental origin stories, both easily wrecked by light.
In plain English
GHRP-6 is a six-amino-acid molecule built in the 1980s to trigger growth hormone release, before anyone knew which receptor it acted on.
PT-141 is a breakdown product of a compound originally developed for research into skin pigmentation. An unexpected observation redirected attention to it.
The difference, without the jargon
Both are good examples of how much of pharmacology happens sideways. GHRP-6 worked on an unknown receptor, and chasing that receptor led to the discovery of the hormone ghrelin years later. PT-141 was a metabolite of a pigmentation-research compound until an unanticipated finding turned it into its own programme. Their research areas are unrelated — growth hormone for one, melanocortin receptors and central nervous system effects for the other. Where they converge is storage: both contain tryptophan, the most light-sensitive amino acid, and both yellow as they degrade. GHRP-6 is the more vulnerable of the two, carrying two copies of it. PT-141 also has a structural quirk worth knowing: it forms a closed ring, but one held by a stable ordinary bond rather than the reactive sulfur bond found in oxytocin.
Common questions
What is the difference between GHRP-6 and PT-141?
GHRP-6 triggers growth hormone release and belongs to endocrine research. PT-141 acts on melanocortin receptors and is studied for central nervous system effects. Different targets and different research areas.
Where did PT-141 come from?
It is a breakdown product of Melanotan II, a compound developed for skin pigmentation research. An unanticipated observation during that work redirected attention to the metabolite, which was then developed separately.
Why do both yellow over time?
Both contain tryptophan, the amino acid most easily damaged by light, and yellowing is that damage becoming visible. It is a reason to discard the vial rather than a cosmetic issue.
Technical reference below
How they actually differ
Comparing the two: GHRP-6 is synthetic hexapeptide, met-enkephalin analogue and ghrelin-receptor agonist, while PT-141 (Bremelanotide) is cyclic heptapeptide, melanocortin receptor agonist — different molecular classes with different handling consequences; they call for different primary diluents (sterile or bacteriostatic water versus bacteriostatic water (0.9% benzyl alcohol)); their leading degradation routes differ (tryptophan photo-oxidation at two independent positions for GHRP-6, tryptophan photo-oxidation for PT-141 (Bremelanotide)), so the storage precautions that matter are not the same; their practical working windows differ once reconstituted. The sections below set out each in full.
GHRP-6 — origin
GHRP-6 was among the first synthetic growth hormone secretagogues, developed from met-enkephalin analogues in the 1980s — years before the ghrelin receptor it acts on was even identified. It is a genuine piece of pharmacological history: the compound was found first and its target second, and that search for the endogenous ligand of its receptor eventually led to the discovery of ghrelin in 1999.
PT-141 (Bremelanotide) — origin
PT-141 is a metabolite of Melanotan II, and its history is an unusually direct case of a side effect becoming the research programme. Melanotan II was developed as a synthetic α-MSH analogue for pigmentation research; an unanticipated effect observed during that work redirected attention to the metabolite, which was then developed separately as bremelanotide.
GHRP-6 research themes
Acts at GHS-R1a — the receptor whose search for an endogenous ligand led to ghrelin's discovery.
Strong GH-releasing activity in research models, historically the compound's defining property.
Ghrelin-receptor activity links it to appetite pathways in metabolic research models.
A landmark in reverse pharmacology: the synthetic ligand preceded knowledge of both receptor and natural ligand.
PT-141 (Bremelanotide) research themes
Acts at melanocortin receptors, with MC3R and MC4R the subtypes of research interest.
Distinguished in the literature by acting centrally, unlike vascular-mechanism compounds in adjacent research areas.
Its origin as a metabolite of a pigmentation-research compound is central to understanding its development history.
The lactam bridge restricts conformational freedom, a common strategy for improving receptor selectivity.
GHRP-6 handling
- Amber vials or foil wrapping should be treated as required, not optional.
- Reconstitute under reduced lighting where practical.
- Avoid contact with trace metals, which catalyse oxidative degradation of aromatic residues.
PT-141 (Bremelanotide) handling
- Protect from light at all stages.
- Standard gentle reconstitution; the constrained ring is not agitation-sensitive in the way flexible long chains are.
- Store refrigerated and aliquot rather than repeatedly sampling one vial.
Both third-party tested
Every Popular Peptides batch of GHRP-6 and PT-141 (Bremelanotide) is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.
GHRP-6 reference
Related comparisons
GHRP-6 and PT-141 (Bremelanotide) are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.